Weight loss drugs based on semaglutide have gained strong popularity worldwide. Two leading names in this class are Wegovy and Ozempic. Both drugs share a common active compound yet target different health goals. Many people now seek detailed guidance to choose between these treatments.
This article unpacks how each medicine works. It explains who can benefit from these injections. Finally, it highlights key differences for safer, more informed choices. Wegovy and Ozempic have reshaped obesity and diabetes care globally.
Wegovy vs Ozempic: Same Drug, Different Purpose
Wegovy and Ozempic share semaglutide as an active ingredient targeting GLP-1 receptors. India Today noted on Jun 24, 2025, that Wegovy uses higher doses for weight loss. By contrast, Ozempic uses lower doses to control blood sugar in type 2 diabetes. Thus, doctors prescribe Wegovy for obesity management and Ozempic for diabetes care.
In India, regulators list Wegovy and Ozempic separately despite the same compound. Wegovy approval focuses on long-term weight loss, while Ozempic approval targets glycemic control. Patients must consult doctors to choose Wegovy or Ozempic based on their health goals.
How They Work: Suppressing Appetite and Controlling Blood Sugar?
Semaglutide in Wegovy and Ozempic mimics the natural hormone GLP-1. First, it slows gastric emptying to extend fullness after meals. Then, it boosts insulin secretion in response to high blood sugar. Also, it curbs glucagon release to reduce sugar production in the liver.
Together, these effects suppress appetite and improve blood sugar control. Clinical trials report an average of 15–20% weight loss with Wegovy and good glycemic control with Ozempic when combined with diet and exercise.
Who Can Use It and Who Should Stay Away?
Wegovy suits adults with a BMI over 30 or a BMI over 27 with related health issues. Ozempic fits adults with type 2 diabetes needing better blood sugar management. Both require medical evaluation before use. Avoid Wegovy or Ozempic if you have a history of pancreatitis, medullary thyroid carcinoma, or multiple endocrine neoplasia syndrome type 2.
Also, do not use these injections during pregnancy or while breastfeeding. Always consult a health professional to confirm eligibility before starting treatment.
Side Effects and Risks: What to Expect?
According to a YouTube video uploaded by JJ Medicine, semaglutide drugs like Ozempic and Wegovy mimic GLP-1 to slow digestion, boost insulin, and curb appetite. Common side effects include nausea, vomiting, diarrhea, constipation, and abdominal discomfort. More serious risks involve pancreatitis, gallbladder issues, and thyroid tumours observed in animal studies.
Hypoglycemia can occur, especially with other diabetes drugs. Gradual dose escalation, medical supervision, and regular monitoring help reduce these risks during Wegovy or Ozempic therapy.
Cost, Availability, and Prescription Trends
In India, Wegovy costs between ₹17,345 and ₹26,015 per month, depending on dose strength. Ozempic has not yet been launched in India, but doctors may recommend Wegovy off-label for combined diabetes and weight loss. Globally, both drugs see rising off-label use for obesity.
Prescription trends show more doctors including semaglutide therapy in weight-management plans. Meanwhile, insurers and regulators debate coverage guidelines to improve patient access to Wegovy and Ozempic.
Both Wegovy and Ozempic offer powerful semaglutide therapy for weight loss and diabetes. Consult a doctor to pick the right drug based on your health profile and lifestyle changes.
